The business case for Decree 2026-288 period underwear: A buyer’s guide
“I have had the privilege of working with pharmacy networks, retailers and category teams across the reusable absorbent hygiene world for more than a decade now, and I have rarely seen an opportunity as exciting and significant as the French government’s new period equity and waste reduction scheme. The 1 October 2026 launch date is challenging and the compliance requirements are unforgiving, but the rewards are significant. To help brands, distributors and private label retailers get ready in time I have put together this five-part blog series.”
Outline
-
-
What Decree 2026-288 establishes and why it matters
-
The four parameters every buyer needs to know
-
The scale of the market and demand assumptions
-
Pharmacy exclusivity until 31 December 2028
-
The five questions every category manager must answer
-
Key takeaways
The French government’s new menstrual equity and waste reduction scheme creates a captive, time-bound and exclusive opportunity for the pharmacy channel, but strict parameters determine which period underwear will qualify for reimbursement. Category buyers, brand managers, product sourcing and procurement managers, purchasing agents, product development managers, commercial directors and business development managers who treat this as a standard category launch will miss the October 2026 launch when publicity is at its peak and consumer interest is strongest.
-
The scheme goes live in autumn 2026, leaving a short window to get product in-store
-
Only menstrual cups and washable period underwear qualify for reimbursement, nothing else
-
Nearly seven million people are eligible, generating demand for about three million units annually
-
Estimated €57 million potential annual market revenue at €19 per unit sold
-
Brand-specific LPP coding is mandatory for reimbursement
-
Supplier certification gaps will block product from qualifying
-
A retail price cap of €19 (including tax) will apply
-
Standard category procurement timelines will not fit this scheme
-
Pharmacies hold exclusive sales rights until the end of 2028
An introduction
Decree No. 2026-288 was published in the Journal Officiel on 18 April 2026, creating the first state-subsidised reimbursement framework for reusable menstrual protection in France. For pharmacy networks, wholesale health distributors and hygiene brands, this is a regulated category opening up on a fixed government timeline, with physical pharmacies as the exclusive sales channel until 31 December 2028, a defined eligible population of around 6.7 million people (a tenth of the French population), and an estimated three million units of annual demand in the initial captive market.
The reimbursement scheme becomes operational on 1 October 2026, to align with the start of the new academic year. The final product specifications were announced on 6 August 2026. That gives purchasing and procurement teams less than two months to make supplier decisions, complete product evaluation, secure a LPP code and have stock on shelf. By any standard procurement timeline that is tight. For a regulated hygiene category with a new compliance stack, it is uncomfortably tight.
This article sets out what the decree says, what it means for your strategy, and questions you need to answer now if you hope to have compliant period underwear on-shelf in time for launch.
What does Decree 2026-288 actually do?
The decree establishes a regulatory and financial framework for the reimbursement of two product categories only: reusable menstrual cups and reusable menstrual underwear. Washable pads and other reusable products are explicitly excluded. Reimbursement will be channelled through Assurance Maladie (national health insurance), with reimbursement codes (LPP codes) issued on a brand-specific basis once the manufacturer has lodged a digital application dossier.
The technical specifications governing eligibility were confirmed on 6 August 2026, following industry consultation. They cover construction and composition, absorption capacity, durability and performance after 52 washes, sizing range and supply chain traceability.
Any part of the underwear that touches the skin must be GOTS-certified organic cotton or lyocell and the entire garment must hold Oeko-Tex Standard 100 certification. At least one absorbency level in a range must absorb more than 20ml, and each range must offer at least eight sizes. And all this must be delivered for a manufacturer price of less than €14.40 (excluding tax), with a retail reference price (including tax) of €19.
Period underwear that cannot demonstrate compliance against the final arrêté will not be issued a code and will not be eligible for reimbursement.
Who is eligible to claim reimbursement for reusable period products under Decree 2026-288?
Two cohorts are covered. First, people with periods who are under 26 years of age, with no income condition attached. Second, beneficiaries of the Complementaire Sante Solidaire (C2S) scheme regardless of age. Each eligible person can claim reimbursement for up to two products per year, calculated on a rolling 12-month basis from their first purchase.
The combined eligible population sits at approximately 6.7 million individuals, which is close to one-tenth of the French population.
How much is reimbursed under the French government scheme?
For under-26s, the state covers 55% to 65% of the product cost. For C2S beneficiaries, coverage is 100% with no out-of-pocket expense. The VAT-inclusive retail price ceiling (Prix Limite de Vente) for menstrual underwear is €19. At the 65% upper reimbursement rate against the €19 cap, the maximum reimbursement to under-26s for a pair of period underwear would be €12.35. Eligible beneficiaries will be able to claim the full purchase price up to €19.
For category buyers, brand managers, product sourcing, purchasing and procurement managers, product development managers, commercial directors and business development managers who are adding period underwear to their portfolio or ensuring that their current period underwear product meets the requirements of the scheme, the practical implication is that supplier cost-of-goods, distributor margin, pharmacy retail margin and tax all have to sit inside that €19 envelope.
Who can sell reimbursable period underwear – and until when?
Until 31 December 2028, sale and reimbursement are restricted to physical retail pharmacies. No supermarkets. No ecommerce. No parapharmacie outside the pharmacy network. For purchasing teams this is the most commercially significant clause in the entire decree.
The exclusivity window protects pharmacy networks from non-specialist channel competition during the early adoption period. It also creates a finite trading runway. Brands and products that establish consumer trust, planogram position and supplier relationships before the channel opens up in 2029 will be in a stronger position when supermarkets and ecommerce eventually compete for the same shelf.
How big is the potential market for subsidised period underwear in France?
The combined under-26 and C2S population sits at approximately 6.7 million eligible individuals. At two products per person per year, the theoretical ceiling is 13.4 million units annually, but industry estimates put initial captive demand at around three million units in year one, reflecting realistic adoption curves and the existence of menstrual cups as an alternative reimbursable product. Even at these conservative estimates we are talking about vast national volumes, with demand is likely to be highest in the weeks following the October launch.
Why standard category procurement timelines will not fit the government scheme
Most pharmacy and distributor purchasing teams are accustomed to procurement cycles measured in 12 to 18 months. But here, the window between the confirmation of specifications (6 August 2026) and the operational launch (1 October 2026) leaves only two months to get products on the shelf in time for the anticipated initial rush of publicity and demand.
In that time, sourcing teams have to complete supplier shortlisting, run product evaluation, verify the full certification criteria, finalise product specifications, packaging and planograms, secure wholesaler logistics and have launch stock in pharmacy. Sequential execution does not fit. Workstreams need to run in parallel from the day a preferred supplier is identified, which means the supplier decision has to happen fast and has to be right first time.
Miss this window and you lose the opportunity to be first-to-market in this competitive space. Without eligible period underwear on pharmacy shelves by the start of October, your company will miss out on its share of the €57 million potential annual market revenue.
Five questions every commercial buyer should be answering now
- Which suppliers in your current shortlist actually hold the full certification stack and can deliver the technical product specifications that are required around absorbency, wash durability and absence of toxic chemicals including PFAS?
- Can your shortlisted suppliers deliver to mass national scale inside the 1 October window without quality drift?
- Does the unit cost from your shortlisted suppliers allow you to hold the €19 retail price cap while protecting the standard 30% pharmacy retail margin?
- What is your contingency if your primary supplier cannot deliver compliant product by October 2026?
If the answer to any of those questions is ‘we’re not sure’, that’s a gap you need to close now.
Next steps: Building the business case
The procurement window for the October launch is narrowing. The next stage in the buying journey is building the business case: modelling the unit economics inside the €19 price cap, calibrating volume against your eligible catchment, and stress-testing whether your shortlisted suppliers can hold pricing without eroding pharmacy margins. The next article in this series walks through how to build that business case, including the four variables that determine whether your numbers stand up, and the questions your CFO will ask before sign-off.
Read more on this topic in this five-blog series
About the author
Frantisek Riha-Scott, Founder and CEO, Confitex Technology
As the tech leader in reusable personal hygiene since 2013, Confitex designs and manufactures award-winning washable period and incontinence products for leading retail, pharmacy and healthcare brands worldwide. Frantisek has spent more than a decade working at the intersection of fashion design, textile engineering and absorbent hygiene manufacturing, and has worked directly with independent laboratories to shape emerging industry performance standards for reusable absorbent hygiene. His perspective on the French menstrual equity and waste reduction scheme is grounded in detailed working knowledge of the certifications required to trade under Decree 2026-288 and in active conversations with organisations preparing for the October 2026 launch. He writes to help pharmacy category managers, hygiene buyers, purchasing directors and procurement leaders cut through the regulatory complexity and make supplier decisions with confidence. Connect with Frantisek on LinkedIn.
